STOCK TITAN

GSK plc (GLAXF) SEC Filings

GLAXF OTC

GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.

The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.

Rhea-AI Summary

On November 20, 2026, GSK plc transferred 22,000,000 treasury ordinary shares to JPMorgan Chase Bank, N.A., the depositary for its ADR programme, to procure the issuance and transfer of 11,000,000 ADRs to the GlaxoSmithKline (US) Trust for awards under three company plans. The consideration received from the Trust’s trustee was $47.82 per ADR, representing $23.91 per ordinary share, funded by a contribution to the Trust from GlaxoSmithKline LLC.

Following the transfer, GSK will hold 248,881,064 ordinary shares in treasury and have 4,067,451,066 ordinary shares in issue, excluding treasury shares. Treasury shares represent 6.12% of voting rights; the total number of voting rights is 4,067,451,066.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

GSK plc (GSK) said the FDA granted accelerated approval for Nelkarmi (neladalkib) for adults with locally advanced or metastatic ALK-positive NSCLC after either alectinib as their only prior ALK TKI, or two or more prior ALK TKIs and platinum-based chemotherapy. The approval came ahead of the FDA's original target action date of November 27, 2026.

In ALKOVE-1, confirmed overall response rates were 49% after alectinib alone (33/67) and 32% after two or more ALK TKIs and chemotherapy (50/155). Among responders, duration of response was at least 6 months for 76% and 69%, respectively, and at least 12 months for 52% and 51%. For patients with measurable CNS metastases, intracranial response rates were 55% and 26% in the respective groups, including complete responses in 25% and 11%. Common adverse reactions (≥20%) included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema and fatigue; 5% permanently discontinued treatment due to adverse reactions. Nelkarmi is also being evaluated in the phase III ALKAZAR trial in TKI-naïve ALK-positive NSCLC and other solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
current report
-
Rhea-AI Summary

GSK plc reported four ADS acquisitions by three executives on November 13, 2026. Non-Executive Director Dr Hal Barron, SVP and Group General Counsel James Ford, and President, US Maya Martinez-Davis acquired 2,259.160, 53.408, and 81.902 notional ADS, respectively, in their GSK Executive Supplemental Savings Plan accounts following dividend reinvestment. Each was priced at $50.4500 per ADS. Dr Barron also acquired 72 ADS in his 401(k) plan account following dividend reinvestment at the same price. The transactions were reported at the New York Stock Exchange.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.00%
Tags
current report
Rhea-AI Summary

GSK plc said the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended updating the Bexsero label to include a single booster dose for people aged 10 years and older who received Bexsero at least two years earlier. The recommendation is based on data showing that immune memory established by vaccination in infancy can be boosted with a single dose up to 19 years later.

The supporting Men-B-096 Phase IIIb study met its primary endpoint. Its single-dose booster safety and reactogenicity were consistent with Bexsero’s known safety profile in this age group. The study enrolled 312 healthy participants aged 10–20 years: 234 had received Bexsero during infancy, and 78 had not previously received a meningococcal B vaccine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
current report
-
Rhea-AI Summary

GSK plc reported acquisitions under its Share Reward Plan on November 10, 2026. Lynn Baxter, CEO, ViiV Healthcare and President, Global Health, GSK; Julie Brown, Chief Financial Officer; David Redfern, President, Corporate Development; Regis Simard, President, Global Supply Chain; James Strenner, President, Europe; Philip Thomson, President, Global Affairs; and Neil Falkingham, a person closely associated with Lynn Baxter, each acquired 12 ordinary shares at £19.3453.

Victoria Whyte, SVP & Company Secretary, acquired 14 ordinary shares at £19.3453. The 12-share transactions comprised 6 partnership shares and 6 matching shares; Whyte’s comprised 7 of each. On November 9, 2026, Maya Martinez-Davis, President, US, acquired 9.264 notional ADS at $51.5400 within her GSK Executive Supplemental Savings Plan account.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
current report
-
Rhea-AI Summary

GSK plc announced provisional dividend dates for 2027; the dates are indicative and may be subject to change. Scheduled payable dates are July 15, 2027, October 14, 2027, January 13, 2028, and April 13, 2028. Ordinary-share ex-dividend dates are May 13, August 12, and November 12, 2027, and February 18, 2028; American Depositary Share ex-dividend dates are May 14, August 13, and November 12, 2027, and February 18, 2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
current report
Rhea-AI Summary

GSK plc, acting as an institutional investment manager, filed a Form 13F holdings report. It lists 13 information-table entries and a reported value total of $497,014,970, rounded to the nearest dollar.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
other
-
Rhea-AI Summary

GSK plc reported 4,045,439,182 total voting rights as of October 31, 2026. Its issued share capital comprised 4,316,320,246 Ordinary Shares of 31 ¼ pence each, including 270,881,064 Ordinary Shares held in Treasury. Shareholders may use the voting-rights figure as the denominator for calculating whether they need to notify an interest or a change in interest under the Financial Conduct Authority’s rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
current report
-
Rhea-AI Summary

GSK plc reported Q3 2026 turnover of £8.887 billion, up 5% at constant exchange rates (CER). Specialty Medicines sales rose 15% CER to £3.877 billion; Vaccines declined 2% to £2.583 billion, while General Medicines was broadly stable at £2.427 billion. Core operating profit rose 5% CER to £3.076 billion and Core EPS rose 1% to 54.6p; total operating profit fell 16% CER to £2.127 billion and total EPS fell 21% to 38.5p.

Major restructuring charges of £328 million for Accelerate Growth contributed to lower total results. Nine-month intangible-asset impairments were £2.1 billion, including £1.334 billion for camlipixant and £371 million for Alector collaboration assets. Q3 cash generated from operations was £3.122 billion; free cash flow was £2.078 billion. GSK reaffirmed 2026 CER guidance: turnover growth of 3% to 5%, Core operating profit growth of 7% to 9%, and Core EPS growth of 7% to 9%. Turnover and Core operating profit were expected in the upper halves of their ranges, and Core EPS in the lower half. The Q3 dividend declared was 17p per share.

The three-year Accelerate Growth programme targets £1.9 billion in annual savings, expected to be fully realised by 2029, against expected total costs of £2.4 billion, including £2.1 billion in cash costs. Savings are primarily intended for reinvestment in R&D.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
current report
Rhea-AI Summary

GSK plc reported positive results from ARTEMIS-011, a pivotal Phase III trial conducted by Hansoh Pharma in China in patients with osteosarcoma that had progressed or relapsed after at least two prior lines of systemic therapy. Ris-Rez reduced the risk of disease progression or death by 67% versus chemotherapy after a median follow-up of 7.1 months. Median progression-free survival was 5.5 months with Ris-Rez and 1.4 months with chemotherapy.

Grade 3 or higher treatment-related adverse events occurred in 93% of patients receiving Ris-Rez and 83% receiving chemotherapy; these events led to treatment discontinuation in 4% and 2%, respectively. The results will support a regulatory submission by Hansoh in China. GSK holds exclusive rights to develop and commercialise Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan, and its global Phase Ib/II EMBOLD Sarcoma-202 trial is ongoing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
current report

FAQ

How many GSK plc (GLAXF) SEC filings are available on StockTitan?

StockTitan tracks 330 SEC filings for GSK plc (GLAXF), including 20-F annual reports and 6-K reports. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for GSK plc (GLAXF)?

The most recent SEC filing for GSK plc (GLAXF) was filed on November 20, 2026.